RHMM retweeted
BREAKING: @OysterPointRx announces preclinical study results, pipeline expansion with Enriched Tear Film (ETF™) #genetherapy to to target #ocularsurfacediseases. #ophthalmology buff.ly/3z7Wd9R
RHMM retweeted
Me looking at the calendar and realizing we're ONE WEEK out from #ARVO2021. Staff are working hard day and night to bring you an incredible virtual experience, and we can't wait to welcome you on May 1!
RHMM retweeted
Look forward to discussing #dryeye disease with Dr.@whitley_walt Dr. Hauswirth
#seco2017 #optometry #SoMe
@Shireplc xiidra.com
RHMM retweeted
Congratulations to Nahum, Ofer, and the entire #EyeYon team! #FDAapproved #VanLeerGrad buff.ly/2aKVK73
RHMM retweeted
.@ShireEyeCare ups visibility at #SECO2016 #optometry
RHMM retweeted
Saunders: Big pharma in 1998 accounted for 62% of new products. In 2013, it only produced 22%. #OISAAO
RHMM retweeted
November is Diabetic Eye Disease Month
read more: macularhope.org
RHMM retweeted
TearScience® announces new pricing strategy for Core LipiFlow®, treatment of dry eye from Meibomian Gland Disease ow.ly/TWY3s
RHMM retweeted
In an average life, your eyes will see 24 million different images #eyefacts
RHMM retweeted
Sean Ianchulev MD describes the potential of supraciliary microstenting with the CyPass Micro-Stent #MIGS #glaucoma ophthalmologytimes.modernmed…
RHMM retweeted
Congratulations to Oculeve. Great to see @Allergan so active in #ophthalmology Innovation. prnewswire.com/news-releases…
RHMM retweeted
Which are the best ophthalmic hospitals in the U.S.? Find out here: buff.ly/1Ig3Fzj
RHMM retweeted
Dr. Scott Schachter explains why dry eye means poor vision buff.ly/1G0kWJ5 #optometry
RHMM retweeted
Ciao #SanFrancisco! Thanks #dryeye experts…See u soon! tfosdewsreport.org/ #DEWSII #innovation #eyeinfo #medtech
RHMM retweeted
KYTHERA Biopharmaceuticals To Present at the 33rd Annual J.P. Morgan Healthcare Conference #KYTHERABIO $KYTH tinyurl.com/m9u9uhh
RHMM retweeted
Salix Pharmaceuticals CEO Plans to Retire on.wsj.com/1vW519e
RHMM retweeted
STAAR cites strong Q1 2013 financial results: total sales up 16% from Q1 2012; Visian ICL sales up 24% prn.to/10W8qMN #ophthalmology























